Summit Therapeutics Net Income Over Time
| SMMT Stock | USD 14.96 0.33 2.26% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Summit Therapeutics Performance and Summit Therapeutics Correlation. Is there potential for Biotechnology market expansion? Will Summit introduce new products? Factors like these will boost the valuation of Summit Therapeutics. If investors know Summit will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Summit Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Summit Therapeutics PLC's market price often diverges from its book value, the accounting figure shown on Summit's balance sheet. Smart investors calculate Summit Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Summit Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Summit Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Summit Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Summit Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Summit Therapeutics PLC and related stocks such as Roivant Sciences, BridgeBio Pharma, and Revolution Medicines Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROIV | (1 B) | (1 B) | (1 B) | (1 B) | (1 B) | (1 B) | (1 B) | (1 B) | (1 B) | 1.2 B | (809.2 M) | (845.3 M) | (1 B) | 4.3 B | (172 M) | (197.8 M) | (187.9 M) |
| BBIO | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (130.7 M) | (260.4 M) | (448.7 M) | (562.5 M) | (481.2 M) | (643.2 M) | (535.8 M) | (482.2 M) | (506.3 M) |
| RVMD | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (41.8 M) | (47.7 M) | (108.2 M) | (187.1 M) | (248.7 M) | (436.4 M) | (600.1 M) | (540.1 M) | (513.1 M) |
| ASND | 1.2 M | 1.2 M | 1.2 M | 4.1 M | (9.7 M) | (32.9 M) | (68.5 M) | (123.9 M) | (130.1 M) | (218 M) | (419 M) | (383.6 M) | (583.2 M) | (481.4 M) | (378.1 M) | (219 M) | (230 M) |
| IONS | (4.5 M) | (84.8 M) | (65.5 M) | (60.6 M) | (39 M) | (88.3 M) | (86.6 M) | 346 K | 273.7 M | 294 M | (487 M) | (28.6 M) | (269.7 M) | (366.3 M) | (453.9 M) | (408.5 M) | (388.1 M) |
| EXAS | (3.6 M) | (28.7 M) | (52.4 M) | (46.5 M) | (100 M) | (157.8 M) | (167.2 M) | (114.4 M) | (175.1 M) | (213.1 M) | (823.6 M) | (595.6 M) | (623.5 M) | (204.1 M) | (1 B) | (207.9 M) | (218.3 M) |
| RPRX | (32.5 M) | (32.5 M) | (32.5 M) | (32.5 M) | (32.5 M) | 581.4 M | 565.9 M | 1.2 B | 1.4 B | 2.3 B | 975 M | 619.7 M | 42.8 M | 1.1 B | 859 M | 770.9 M | 958.2 M |
| MRNA | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (1.1 M) | (216.2 M) | (255.9 M) | (384.7 M) | (514 M) | (747.1 M) | 12.2 B | 8.4 B | (4.7 B) | (3.6 B) | (2.8 B) | (2.7 B) |
| RNA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (24.7 M) | (44 M) | (117.4 M) | (169.1 M) | (212.2 M) | (322.3 M) | (290.1 M) | (275.6 M) |
| UHS | 21.7 M | 398.2 M | 443.4 M | 510.7 M | 545.3 M | 680.5 M | 702.4 M | 752.3 M | 779.7 M | 814.9 M | 944 M | 991.6 M | 675.6 M | 717.8 M | 1.1 B | 1.3 B | 1.4 B |
Summit Therapeutics PLC and related stocks such as Roivant Sciences, BridgeBio Pharma, and Revolution Medicines Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Summit Therapeutics PLC financial statement analysis. It represents the amount of money remaining after all of Summit Therapeutics PLC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Summit Therapeutics PLC | SMMT |
| Classification | Israel Wall Street |
| Business Address | 601 Brickell Key |
| Exchange | NASDAQ Exchange |
USD 14.96
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.